3-ethoxycarbonylmethyl-indole-2-carboxylic acid | 96296-38-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-ethoxycarbonylmethyl-indole-2-carboxylic acid
• 英文别名: 3-Aethoxycarbonylmethyl-indol-2-carbonsaeure；Ethyl-2-carboxyindol-3-acetat；3-(2-ethoxy-2-oxoethyl)-1H-indole-2-carboxylic acid
• CAS: 96296-38-7
• 化学式: C₁₃H₁₃NO₄
• mdl: MFCD00227415
• 分子量: 247.251
• InChiKey: KQSJKIFUOUFTQO-UHFFFAOYSA-N

物化性质

• 熔点：
  175-176 °C
• 沸点：
  459.4±30.0 °C(Predicted)
• 密度：
  1.345±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  79.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-ethoxycarbonylmethyl-indole-2-carboxylic acid 在 喹啉 、 copper(I) oxide 、 氢氧化钾 作用下， 生成 3-吲哚乙酸
  参考文献：
  名称：

  SYNTHESIS OF INDOLEACETIC ACIDS

  摘要：

  不可用。

  DOI：

  10.1139/v57-208
• 作为产物：
  描述：

  3-(羧甲基)-1H-吲哚-2-羧酸 在 盐酸 作用下， 生成 3-ethoxycarbonylmethyl-indole-2-carboxylic acid
  参考文献：
  名称：

  SYNTHESIS OF INDOLEACETIC ACIDS

  摘要：

  不可用。

  DOI：

  10.1139/v57-208

文献信息

• New indole derivatives as factor Xa inhibitors
  申请人：——

  公开号：US20030199689A1

  公开（公告）日：2003-10-23

  The present invention relates to compounds of formula I, 1 in which R 0 ; R 1 ; R 2 ; R 3 ; R 4 ; R 5 ; R 6 ; R 7 ; Q; V, G and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is indicated. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as pharmaceuticals for treating the foregoing conditions, and pharmaceutical preparations comprising them.

  本发明涉及具有式I的化合物，其中R0；R1；R2；R3；R4；R5；R6；R7；Q；V，G和M具有索赔中指示的含义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，例如，适用于治疗和预防心血管疾病如血栓栓塞疾病或再狭窄。它们是血凝酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，通常可应用于存在因子Xa和/或因子VIIa不良活性的情况，或者在其治疗或预防需要抑制因子Xa和/或因子VIIa的情况下。此外，本发明还涉及制备式I化合物的方法，它们的用途，特别是作为用于治疗上述疾病的药物，以及包含它们的制剂。
• INDOLES
  申请人：Bissantz Caterina

  公开号：US20080139548A1

  公开（公告）日：2008-06-12

  The present invention is concerned with novel indol-2-yl-carbonyl-piperidin-benzoimidazolon and indol-2-yl-carbonyl-piperidin-benzoxazolon derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases. In particular, the present invention concerns compounds of formula (I) wherein R 1 to R 11 , X and Y are as defined in the specification.

  本发明涉及新颖的吲哒-2-基-羰基-哌啶-苯并咪唑酮和吲哒-2-基-羰基-哌啶-苯并噁唑酮衍生物作为V1a受体拮抗剂，它们的制备，含有它们的药物组合物以及它们用于治疗焦虑和抑郁症及其他疾病。具体而言，本发明涉及式(I)的化合物，其中R1至R11，X和Y如规范中定义。
• New indole derivatives as factor xa inhibitors
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1479677A1

  公开（公告）日：2004-11-24

  The present invention relates to compounds of the formula I, in which R0 ; R1 ; R2 ; R3 ; R4 ; R5 ; R6 ; R7 ; Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及具有式I的化合物，其中R0；R1；R2；R3；R4；R5；R6；R7；Q；V，G和M具有索示的含义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，例如，适用于治疗和预防心血管疾病，如血栓栓塞疾病或再狭窄。它们是血液凝块酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，通常可用于存在因子Xa和/或FVIIa的不良活性的情况，或者用于治疗或预防需要抑制因子Xa和/或FVIIa的疾病。此外，本发明还涉及制备式I化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的药物制剂。
• Indole derivatives as factor Xa inhibitors
  申请人：Nazare Marc

  公开号：US20050033049A1

  公开（公告）日：2005-02-10

  The present invention is directed to the compound of formula I which is useful for inhibiting the activity of Factor Xa. The present invention is also directed to compositions containing said compounds, processes for their preparation, their use, such as for inhibiting the formation of thrombin or for therapeutically or prophylactically treating a patient suffering from, or subject to, or associated with a disease state associated with a cardiovascular disorder.

  本发明涉及一种具有化学式I的化合物，用于抑制因子Xa的活性。本发明还涉及含有上述化合物的组合物，其制备过程，以及它们的用途，例如用于抑制凝血酶的形成，或用于治疗或预防患有与心血管疾病有关的疾病状态的患者。
• Indoles
  申请人：Bissantz Caterina

  公开号：US20080269290A1

  公开（公告）日：2008-10-30

  The present invention is concerned with novel indol-2-yl-carbonyl-piperidin-benzoimidazolon and indol-2-yl-carbonyl-piperidin-benzoxazolon derivatives as V1 a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases. In particular, the present invention concerns compounds of formula (I) wherein R 1 to R 11 , X and Y are as defined in the specification.

  本发明涉及新型的indol-2-yl-carbonyl-piperidin-benzoimidazolon和indol-2-yl-carbonyl-piperidin-benzoxazolon衍生物，作为V1a受体拮抗剂，它们的制造，包含它们的制药组合物以及它们用于治疗焦虑和抑郁症以及其他疾病的用途。特别地，本发明涉及式(I)中R1到R11、X和Y所定义的化合物。